Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 11, 2013, Pages 1338-1350

  Iannitti, Rossana G ^a   Casagrande, Andrea ^a,b   De Luca, Antonella ^a   Cunha, Cristina ^a   Sorci, Guglielmo ^a   Riuzzi, Francesca ^a   Borghi, Monica ^a   Galosi, Claudia ^a   Massi Benedetti, Cristina ^a   Oury, Tim D ^c   Cariani, Lisa ^d   Russo, Maria ^d   Porcaro, Luigi ^d   Colombo, Carla ^d   Majo, Fabio ^e   Lucidi, Vincenzina ^e   Fiscarelli, Ersilia ^e   Ricciotti, Gabriella ^e   Lass Flörl, Cornelia ^f   Ratclif, Luigi ^g   Esposito, Antonella ^h   De Benedictis, Fernando Maria ⁱ   Donato, Rosario ^a   Carvalho, Agostinho ^a   Romani, Luigina ^a   more..

^a UNIVERSITY OF PERUGIA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g Istituto Ospedale G Tatarella   (Italy)

^h Hospital of Foligno   (Italy)

ⁱ Salesi Children's Hospital   (Italy)

Author keywords

Cystic fibrosis; Hypoxia; Infections; Inflammation; Rage

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLOSIS; BACTERIAL PNEUMONIA; CONTROLLED STUDY; CYSTIC FIBROSIS; EPITHELIUM CELL; GENETIC VARIABILITY; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG MYCOSIS; MALE; MOUSE; NONHUMAN; PATHOGEN CLEARANCE; PATHOGEN LOAD; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFLAMMATION; SIGNAL TRANSDUCTION; STABLE EXPRESSION;

ANIMALS; ANOXIA; ASPERGILLOSIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CYSTIC FIBROSIS; DRUG RESISTANCE, MICROBIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; ITALY; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PNEUMONIA; PSEUDOMONAS INFECTIONS; RECEPTORS, IMMUNOLOGIC; RESPIRATORY MUCOSA; TISSUE CULTURE TECHNIQUES; UP-REGULATION;

EID: 84890080324     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201305-0986OC     Document Type: Article

References (78)

1. Cantin A. Cystic fibrosis lung inflammation: early, sustained, and severe. Am J Respir Crit Care Med 1995;151:939-941.
2. Hoffman LR, Ramsey BW. Cystic fibrosis therapeutics: the road ahead. Chest 2013;143:207-213.
3. Hartl D, Gaggar A, Bruscia E, Hector A, Marcos V, Jung A, Greene C, McElvaney G, Mall M, Döring G. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 2012;11:363-382.
4. Mizgerd JP, Lupa MM, Kogan MS, Warren HB, Kobzik L, Topulos GP. Nuclear factor-kappaB p50 limits inflammation and prevents lung injury during Escherichia coli pneumonia. Am J Respir Crit Care Med 2003;168:810-817.
5. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012;18:509-519.
6. Corvol H, Fitting C, Chadelat K, Jacquot J, Tabary O, Boule M, Cavaillon JM, Clement A. Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2003;284:L997-L1003.
7. IannittiRG,Carvalho A, CunhaC, De Luca A, Giovannini G, Casagrande A, Zelante T, Vacca C, Fallarino F, Puccetti P, et al. Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines. Am J Respir Crit Care Med 2013;187:609-620.
8. Robinson KM, Alcorn JF. T-cell immunotherapy in cystic fibrosis: weighing the risk/reward. Am J Respir Crit CareMed 2013;187:564-566.
9. Legendre C,MooijMJ, Adams C,O'Gara F. Impaired expression of hypoxiainducible factor-1a in cystic fibrosis airway epithelial cells: a role for HIF-1 in the pathophysiology of CF? J Cyst Fibros 2011;10:286-290.
10. Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2013;7:CD003884.
11. Duranton C, Rubera I, Cougnon M, Melis N, Chargui A, Mograbi B, Tauc M. CFTR is involved in the fine tuning of intracellular redox status: physiological implications in cystic fibrosis. Am J Pathol 2012; 181:1367-1377.
12. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001;13:167-171.
13. Shimoda LA, Semenza GL. HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med 2011;183:152-156.
14. Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, Semenza GL. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 1998;275:L818-L826.
15. Peyssonaux C, Johnson RS. An unexpected role for hypoxic response: oxygenation and inflammation. Cell Cycle 2004;3:168-171.
16. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen HR, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1 Cell 2011;146:772-784.
17. Shi LZ, Wang R,HuangG, Vogel P, Neale G,Green DR, ChiH. HIF1alphadependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J ExpMed 2011;208:1367-1376.
18. Herbert A, Ng H, JessupW, KockxM, Cartland S, Thomas SR, Hogg PJ, Wargon O. Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine 2,3-dioxygenase in monocyte-derived endothelial-like cells: possible relevance to infantile haemangioma pathogenesis. Br J Dermatol 2011;164:308-315.
19. Roth A, König P, van Zandbergen G, Klinger M, Hellwig-Bürgel T, Däubener W, Bohlmann MK, Rupp J. Hypoxia abrogates antichlamydial properties of IFN-g in human fallopian tube cells in vitro and ex vivo. Proc Natl Acad Sci USA 2010;107:19502-19507.
20. Sica A, Melillo G, Varesio L. Hypoxia: a double-edged sword of immunity. J Mol Med (Berl) 2011;89:657-665.
21. Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL, Jedlicka P, de Zoeten EF, Cambier JC, Stenmark KR, Colgan SP, et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA 2012;109:E2784-E2793.
22. Pichiule P, Chavez JC, Schmidt AM, Vannucci SJ. Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia. J Biol Chem 2007; 282:36330-36340.
23. Makam M, Diaz D, Laval J, Gernez Y, Conrad CK, Dunn CE, Davies ZA, Moss RB, Herzenberg LA, Herzenberg LA, et al. Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proc Natl Acad Sci USA 2009;106: 5779-5783.
24. Mukherjee TK, Mukhopadhyay S, Hoidal JR. Implication of receptor for advanced glycation end product (RAGE) in pulmonary health and pathophysiology. Respir Physiol Neurobiol 2008;162:210-215.
25. Corvol H, Beucher J, Boëlle PY, Busson PF, Muselet-Charlier C, Clement A, Ratjen F, Grasemann H, Laki J, Palmer CN, et al. Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. J Cyst Fibros 2012;11:63-67.
26. Beucher J, Boëlle PY, Busson PF, Muselet-Charlier C, Clement A, Corvol H; French C F Modifier Gene Study Investigators. AGER-429T/C is associated with an increased lung disease severity in cystic fibrosis. PLoS ONE 2012;7:e41913.
27. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, Franceschini N, van Durme YM, Chen TH, Barr RG, et al. Metaanalyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 2010;42:45-52.
28. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, Zhao JH, Ramasamy A, Zhai G, Vitart V, et al.; Wellcome Trust Case Control Consortium; NSHD Respiratory Study Team. Genomewide association study identifies five loci associated with lung function. Nat Genet 2010;42:36-44.
29. Han SH, Kim YH, Mook-Jung I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011;31:91-97.
30. Sukkar MB, Wood LG, Tooze M, Simpson JL, McDonald VM, Gibson PG, Wark PA. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J 2012;39:721-729.
31. Zhang H, Tasaka S, Shiraishi Y, Fukunaga K, Yamada W, Seki H, Ogawa Y, Miyamoto K, Nakano Y, Hasegawa N, et al. Role of soluble receptor for advanced glycation end products on endotoxininduced lung injury. Am J Respir Crit Care Med 2008;178:356-362.
32. Creagh-Brown BC, Burke-Gaffney A, Evans TW. sRAGE: a useful biomarker in acute lung injury? Crit Care Med 2011;39:589-590.
33. Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010;2: 1184-1195.
34. Sukkar MB, Ullah MA, Gan WJ, Wark PA, Chung KF, Hughes JM, Armour CL, Phipps S. RAGE: a new frontier in chronic airways disease. Br J Pharmacol 2012;167:1161-1176.
35. Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, Boyle MP. Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. J Cyst Fibros 2010;9:110-116.
36. Wezensky SJ, Cramer RA Jr. Implications of hypoxic microenvironments during invasive aspergillosis. Med Mycol 2011;49:S120-S124.
37. Sorci G, Giovannini G, Riuzzi F, Bonifazi P, Zelante T, Zagarella S, Bistoni F, Donato R, Romani L. The danger signal S100B integrates pathogen-and danger-sensing pathways to restrain inflammation. PLoS Pathog 2011;7:e1001315.
38. Cunha C, Giovannini G, Pierini A, Bell AS, Sorci G, Riuzzi F, Donato R, Rodrigues F, Velardi A, Aversa F, et al. Genetically-determined hyperfunction of the S100B/RAGE axis is a risk factor for aspergillosis in stem cell transplant recipients. PLoS ONE 2011;6:e27962.
39. Legendre C, Reen FJ, Mooij MJ, McGlacken GP, Adams C, O'Gara F. Pseudomonas aeruginosa Alkyl quinolones repress hypoxia-inducible factor 1 (HIF-1) signaling through HIF-1a degradation. Infect Immun 2012;80:3985-3992.
40. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F, Tubaro C, Giambanco I. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 2009;1793:1008-1022.
41. Rizzetto L, Giovannini G, Bromley M, Bowyer P, Romani L, Cavalieri D. Strain dependent variation of immune responses to A. fumigatus: definition of pathogenic species. PLoS ONE 2013;8:e56651.
42. Peluso L, de Luca C, Bozza S, Leonardi A, Giovannini G, Lavorgna A, De Rosa G, Mascolo M, Ortega De Luna L, Catania MR, et al. Protection against Pseudomonas aeruginosa lung infection in mice by recombinant OprF-pulsed dendritic cell immunization. BMC Microbiol 2010;10:9.
43. Moalli F, Paroni M, Véliz Rodriguez T, Riva F, Polentarutti N, Bottazzi B, Valentino S, Mantero S, Nebuloni M, Mantovani A, et al. The therapeutic potential of the humoral pattern recognition molecule PTX3 in chronic lung infection caused by Pseudomonas aeruginosa. J Immunol 2011;186:5425-5434.
44. Galietta LJ, Folli C, Marchetti C, Romano L, Carpani D, Conese M, Zegarra-Moran O. Modification of transepithelial ion transport in human cultured bronchial epithelial cells by interferon-gamma. Am J Physiol Lung Cell Mol Physiol 2000;278:L1186-L1194.
45. Gefter JV, Shaufl AL, Fink MP, Delude RL. Comparison of distinct protein isoforms of the receptor for advanced glycation endproducts expressed in murine tissues and cell lines. Cell Tissue Res 2009;337:79-89.
46. Ramsgaard L, Englert JM, Manni ML, Milutinovic PS, Gefter J, Tobolewski J, Crum L, Coudriet GM, Piganelli J, Zamora R, et al. Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice. PLoS ONE 2011;6:e20132.
47. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001;50:1495-1504.
48. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, Lerner S, Bakr S, Li Q, Lu Y, et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006;113:1226-1234.
49. Grahl N, Puttikamonkul S, Macdonald JM, Gamcsik MP, Ngo LY, Hohl TM, Cramer RA. In vivo hypoxia and a fungal alcohol dehydrogenase influence the pathogenesis of invasive pulmonary aspergillosis. PLoS Pathog 2011;7:e1002145.
50. Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC, Thompson CB. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 2007;21:1037-1049.
51. Ahmad T, Kumar M, Mabalirajan U, Pattnaik B, Aggarwal S, Singh R, Singh S, Mukerji M, Ghosh B, Agrawal A. Hypoxia response in asthma: differential modulation on inflammation and epithelial injury. Am J Respir Cell Mol Biol 2012;47:1-10.
52. Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S, O'Neill SJ, McElvaney NG. TLR-induced inflammation in cystic fibrosis and noncystic fibrosis airway epithelial cells. J Immunol 2005;174:1638-1646.
53. Parker D, Cohen TS, Alhede M, Harfenist BS, Martin FJ, Prince A. Induction of type I interferon signaling by Pseudomonas aeruginosa is diminished in cystic fibrosis epithelial cells. Am J Respir Cell Mol Biol 2012;46:6-13.
54. Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids 2012;42:1151-1161.
55. Brisslert M, Amu S, Pullerits R. Intra-peritoneal sRAGE treatment induces alterations in cellular distribution of CD19(1), CD3 (1) and Mac-1 (1) cells in lymphoid organs and peritoneal cavity. Cell Tissue Res 2013;351:139-148.
56. Englert JM, Ramsgaard L, Valnickova Z, Enghild JJ, Oury TD. Large scale isolation and purification of soluble RAGE from lung tissue. Protein Expr Purif 2008;61:99-101.
57. Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev 2012;249: 158-175.
58. Shin HS, Lee JH, Paek SH, Jung YW, Ha UH. Pseudomonas aeruginosadependent upregulation of TLR2 influences host responses to a secondary Staphylococcus aureus infection. Pathog Dis 2013;69:149-156.
59. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001;50:1505-1511.
60. Heo YJ, Oh HJ, Jung YO, Cho ML, Lee SY, Yu JG, Park MK, Kim HR, Lee SH, Park SH, et al. The expression of the receptor for advanced glycation end-products (RAGE) in RA-FLS is induced by IL-17 via Act-1. Arthritis Res Ther 2011;13:R113.
61. Zelante T, Iannitti RG, De Luca A, Arroyo J, Blanco N, Servillo G, Sanglard D, Reichard U, Palmer GE, Latgè JP, et al. Sensing of mammalian IL-17A regulates fungal adaptation and virulence. Nat Commun 2012;3:683.
62. Entezari M, Weiss DJ, Sitapara R, Whittaker L, Wargo MJ, Li J, Wang H, Yang H, Sharma L, Phan BD, et al. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol Med 2012;18:477-485.
63. Muir A, Soong G, Sokol S, Reddy B, Gomez MI, Van Heeckeren A, Prince A. Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 2004;30:777-783.
64. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010;79:1379-1386.
65. Kalea AZ, Schmidt AM, Hudson BI. Alternative splicing of RAGE: roles in biology and disease. Front Biosci (Landmark Ed) 2011;16:2756-2770.
66. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008;22:3716-3727.
67. Metz VV, Kojro E, Rat D, Postina R. Induction of RAGE shedding by activation of G protein-coupled receptors. PLoS ONE 2012;7: e41823.
68. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-1109.
69. Chang JS, Wendt T, Qu W, Kong L, Zou YS, Schmidt AM, Yan SF. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res 2008; 102:905-913.
70. Koulmann N, Novel-Chaté V, Peinnequin A, Chapot R, Serrurier B, Simler N, Richard H, Ventura-Clapier R, Bigard X. Cyclosporin A inhibits hypoxia-induced pulmonary hypertension and right ventricle hypertrophy. Am J Respir Crit Care Med 2006;174:699-705.
71. Schults MA, Timmermans L, Godschalk RW, Theys J, Wouters BG, van Schooten FJ, Chiu RK. Diminished carcinogen detoxification is a novel mechanism for hypoxia-inducible factor 1-mediated genetic instability. J Biol Chem 2010;285:14558-14564.
72. Chiba T, Uchi H, Yasukawa F, Furue M. Role of the arylhydrocarbon receptor in lung disease. Int Arch Allergy Immunol 2011;155:129-134.
73. Melillo G. HIF-1: a target for cancer, ischemia and inflammation-too good to be true? Cell Cycle 2004;3:154-155.
74. Schaible B, Schaffer K, Taylor CT. Hypoxia, innate immunity and infection in the lung. Respir Physiol Neurobiol 2010;174:235-243.
75. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-325.
76. Schaible B, Taylor CT, Schaffer K. Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa through altering the composition of multidrug efflux pumps. Antimicrob Agents Chemother 2012;56:2114-2118.
77. Barker BM, Kroll K, Vödisch M, Mazurie A, Kniemeyer O, Cramer RA. Transcriptomic and proteomic analyses of the Aspergillus fumigatus hypoxia response using an oxygen-controlled fermenter. BMC Genomics 2012;13:62.
78. Shepardson KM, Ngo LY, Aimanianda V, Latgé JP, Barker BM, Blosser SJ, Iwakura Y, Hohl TM, Cramer RA. Hypoxia enhances innate immune activation to Aspergillus fumigatus through cell wall modulation. Microbes Infect 2013;15:259-269.